(Q35006397)

5 August 2017

1 reference

title

Overtreatment in adults with epilepsy (English)

1 reference

5 August 2017

Charles L P Deckers

1

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

52

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

43-52

1 reference

Reduction of polypharmacy in epileptic patients.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Is refractory epilepsy preventable?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Quality of care of epilepsy in Italy: multi-hospital survey of diagnosis and treatment of 1104 epileptic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Antiepileptic drugs as 'tracers' of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption. The Group for the Study of Epilepsy in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Managing epilepsy in general practice: the dissemination and uptake of a free audit package, and collated results from 12 practices in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan - a pharmaco-epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Collaborative Group for the Study of Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Place of polytherapy in the early treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Adverse effects in epilepsy therapy. Wait and see or go for it?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Drug load in clinical trials: a neglected factor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

An open multicentre prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic-clonic seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

The early identification of candidates for epilepsy surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Adverse events related to drugs and drug withdrawal in nursing home residents

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Epilepsy after the first drug fails: substitution or add-on?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Effectiveness of first antiepileptic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Strategies for optimizing antiepileptic drug therapy in elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Use of antiepileptic drugs in a community-dwelling Dutch population.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

An audit of treated epilepsy in Glasgow. West of Scotland Epilepsy Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

One drug (phenytoin) in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Antiepileptic drug utilization: a Danish prescription database analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Reduction of two-drug therapy in intractable epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Does antiepileptic drug therapy prevent the development of "chronic" epilepsy?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Unnecessary polypharmacy for epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

One drug for epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Reduction in polypharmacy for epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Anticonvulsant drugs and cognitive functions.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

The use of antiepileptic drugs in learning disabled people with epilepsy: an audit of adult in-patients in a treatment and continuing care service

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

An outcome audit at the epilepsy clinic: results from 1000 consecutive referrals

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900184-5

7 January 2021

10.1016/S0920-1211(02)00184-5

Identifiers

DOI

1 reference

5 August 2017

1 reference